- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Cyclerion and Korsana Announce Merger to Advance Alzheimer's Treatments
Combined company to operate as Korsana Biosciences and focus on developing innovative therapies for neurodegenerative diseases.
Apr. 2, 2026 at 6:24am
Got story updates? Submit your updates here. ›
Cyclerion Therapeutics and Korsana Biosciences, a privately-held biotech company, have announced a definitive merger agreement in an all-stock transaction. The combined company will operate under the Korsana Biosciences name and focus on advancing Korsana's pipeline of therapies for neurodegenerative disorders, starting with its lead program KRSA-028 for the treatment of Alzheimer's disease.
Why it matters
The merger combines Cyclerion's resources with Korsana's promising pipeline of next-generation therapies targeting devastating neurological conditions. With a $380 million private financing commitment, the combined company is well-positioned to accelerate the development of KRSA-028 and Korsana's broader portfolio of innovative treatments for patients in need.
The details
Under the terms of the agreement, Cyclerion shareholders will own approximately 1.5% of the combined company, while Korsana stockholders (including new investors) will own around 98.5%. The transaction is expected to close in Q3 2026, subject to shareholder and regulatory approvals. Korsana's CEO Jonathan Violin will lead the combined company, which plans to trade on Nasdaq under the ticker 'KRSA'.
- The transaction is expected to close in the third quarter of 2026.
- Korsana expects to report Phase 1 healthy volunteer data for KRSA-028 in mid-2027.
- Korsana anticipates interim proof-of-concept data measuring amyloid plaque clearance in Alzheimer's patients by the end of 2027.
The players
Korsana Biosciences
A privately-held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases.
Cyclerion Therapeutics
A biopharmaceutical company focused on developing treatments for neuropsychiatric diseases.
Jonathan Violin, Ph.D.
Korsana's President and Chief Executive Officer, who will lead the combined company.
Regina Graul, Ph.D.
President and Chief Executive Officer of Cyclerion.
Tomas Kiselak
Founding Partner at Fairmount, who will chair the combined company's Board of Directors.
What they’re saying
“Korsana is determined to deliver breakthrough medicines for patients suffering from neurodegenerative disorders. With our seasoned team and support from leading biotechnology investors, Korsana is well-positioned to advance a pipeline of innovative, next generation therapies.”
— Jonathan Violin, Ph.D., Korsana's President and Chief Executive Officer
“Our transaction with Korsana is the result of a comprehensive strategic review, and we believe it represents the best path forward for Cyclerion.”
— Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This merger highlights the growing focus on developing innovative treatments for Alzheimer's and other neurodegenerative diseases, as the combined company aims to leverage its resources and expertise to advance promising therapies and provide new hope for patients.
